Radioimmunotherapy for Waldenstrom's macroglobulinemia

Seminars in Oncology

Volumn 30, Issue 2, 2003, Pages 258-261

  Emmanouilides, Christos ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; INDIUM 111; TOSITUMOMAB I 131;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW METASTASIS; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETREATMENT; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0037396184     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50059     Document Type: Article

References (20)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000
2. Dimopoulos MA, O'Brien S, Kantarjian H, et al: Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. Leuk Lymphoma 11:105-108, 1993 (suppl 2)
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
4. Anderson DR, Grillo-Lopez A, Varns C, et al: Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25:705-708, 1997
5. Alas S, Bonavida B, Emmanouilides C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 20:2961-2966, 2000
6. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
7. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683, 2000
8. Byrd JC, White CA, Link B, et al: Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity. Ann Oncol 10:1525-1527, 1999
9. Treon SP, Agus DB, Link B, et al: CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 24:272-279, 2001
10. Dimopoulos MA, Zervas C, Zomas A, et al: Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20:2327-2333, 2002
11. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
12. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993
13. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
14. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
15. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
16. Wiseman GA, White CA, Witzig TE, et al: Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5:3281s-3286s, 1999 (suppl 10)
17. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al: Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 12:109-114, 2001
18. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
19. Wiseman GA, White CA, Sparks RB, et al: Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39:181-194, 2001
20. Emmanouilides C: Successful treatment of Waldenstrom's macroglobulinemia with Zevalin-based therapy. Blood 98:241b, 2001